For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Vascular Cell Adhesion Molecule-1 (VCAM-1) is a transmembrane glycoprotein with a molecular weight of 110 kDa. VCAM-1 contains six to seven immunoglobulin domains and is expressed on vascular endothelial cells of both small and large blood vessels after stimulation via cytokines (i.e. TNFα, IL-4). It mediates immune system response by recruiting additional immune cells to sites of inflammation. After VCAM-1 binds to either Very Late Antigen 4 (VLA-4) or Integrin receptor α4β7 a proteolytic ectodomain shedding process triggers the release of a soluble form of VCAM-1 (sVCAM-1). This soluble form can be utilized as an inflammatory biomarker. Serum levels of sVCAM-1 have been found to be altered in patients with cancer, diabetes, atherosclerosis, rheumatoid arthritis, and other autoimmune diseases. The AlphaLISA kit presented here detects sVCAM-1 in serum, plasma, and cell culture media.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
|Assay Target Class||Protein|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||100 assay points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater ...